CN107721931A - 吡啶衍生物 - Google Patents

吡啶衍生物 Download PDF

Info

Publication number
CN107721931A
CN107721931A CN201710933918.5A CN201710933918A CN107721931A CN 107721931 A CN107721931 A CN 107721931A CN 201710933918 A CN201710933918 A CN 201710933918A CN 107721931 A CN107721931 A CN 107721931A
Authority
CN
China
Prior art keywords
carbon number
methyl
alkyl
compound
bases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710933918.5A
Other languages
English (en)
Chinese (zh)
Inventor
丸山明伸
镰田大史
藤沼美香
竹内进
斋藤博
高桥良昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of CN107721931A publication Critical patent/CN107721931A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
CN201710933918.5A 2012-11-14 2013-11-13 吡啶衍生物 Pending CN107721931A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-250661 2012-11-14
JP2012250661 2012-11-14
CN201380059519.0A CN104797570B (zh) 2012-11-14 2013-11-13 吡啶衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380059519.0A Division CN104797570B (zh) 2012-11-14 2013-11-13 吡啶衍生物

Publications (1)

Publication Number Publication Date
CN107721931A true CN107721931A (zh) 2018-02-23

Family

ID=50731196

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380059519.0A Expired - Fee Related CN104797570B (zh) 2012-11-14 2013-11-13 吡啶衍生物
CN201710933918.5A Pending CN107721931A (zh) 2012-11-14 2013-11-13 吡啶衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201380059519.0A Expired - Fee Related CN104797570B (zh) 2012-11-14 2013-11-13 吡啶衍生物

Country Status (36)

Country Link
US (2) US9637469B2 (enExample)
EP (2) EP3339302A1 (enExample)
JP (2) JP5774238B2 (enExample)
KR (1) KR20150082194A (enExample)
CN (2) CN104797570B (enExample)
AR (1) AR093468A1 (enExample)
AU (2) AU2013345894B2 (enExample)
BR (1) BR112015010977A2 (enExample)
CA (1) CA2891408A1 (enExample)
CL (1) CL2015001279A1 (enExample)
CY (1) CY1120127T1 (enExample)
DK (1) DK2944633T3 (enExample)
ES (1) ES2662444T3 (enExample)
HR (1) HRP20180451T1 (enExample)
HU (1) HUE037736T2 (enExample)
IL (2) IL238539A (enExample)
LT (1) LT2944633T (enExample)
MA (1) MA38078B1 (enExample)
ME (1) ME03016B (enExample)
MX (1) MX2015003672A (enExample)
NO (1) NO2944633T3 (enExample)
NZ (1) NZ708031A (enExample)
PE (1) PE20150974A1 (enExample)
PH (1) PH12015501037A1 (enExample)
PL (1) PL2944633T3 (enExample)
PT (1) PT2944633T (enExample)
RS (1) RS57090B1 (enExample)
RU (1) RU2640588C2 (enExample)
SA (1) SA515360431B1 (enExample)
SG (2) SG11201503770VA (enExample)
SI (1) SI2944633T1 (enExample)
SM (1) SMT201800322T1 (enExample)
TW (1) TWI666205B (enExample)
UA (1) UA117359C2 (enExample)
WO (1) WO2014077285A1 (enExample)
ZA (1) ZA201503322B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170003569A (ko) * 2014-05-13 2017-01-09 데이진 화-마 가부시키가이샤 피리딘 유도체의 신규 결정 다형체 및 그 제조 방법
NO3144306T3 (enExample) * 2014-05-13 2018-04-14
US20200288710A1 (en) 2016-03-15 2020-09-17 Bayer Cropscience Aktiengesellschaft Substituted sulphonamides for controlling animal pests
CN107286156A (zh) * 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
CA3025078C (en) * 2016-05-23 2021-04-13 Cstone Pharmaceutical (Suzhou) Co., Ltd. Thiophene, manufacturing method thereof, and pharmaceutical application of same
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
UY37557A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas
AU2018207776B2 (en) 2017-01-10 2021-06-17 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
CN108658879A (zh) * 2017-03-29 2018-10-16 天津药物研究院有限公司 一种urat1抑制剂及其制备方法和用途
CN109251184B (zh) * 2017-07-13 2021-06-15 浙江海正药业股份有限公司 一种2-三氟甲基苯磺酰胺类衍生物的医药用途
WO2019226213A2 (en) 2018-03-08 2019-11-28 Incyte Corporation AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
JP2023501978A (ja) 2019-11-07 2023-01-20 バイエル・アクチエンゲゼルシヤフト 動物害虫駆除用の置換スルホニルアミド
KR20230039665A (ko) 2020-07-02 2023-03-21 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
CN114315729B (zh) * 2021-12-09 2024-01-26 大连理工大学 1-苄基-2,4-二芳基咪唑类化合物、合成方法及其在抗肿瘤上的应用
WO2025026738A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009148599A1 (en) * 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
CN101918377A (zh) * 2007-11-27 2010-12-15 亚德生化公司 新颖化合物和组合物以及使用方法
CN102548964A (zh) * 2009-07-10 2012-07-04 通用医疗公司 不抑制肾上腺皮质类固醇合成的依托咪酯类似物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1599032A (en) 1977-03-04 1981-09-30 May & Baker Ltd Imidazole derivatives having herbicidal activity
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
US4770689A (en) 1986-03-10 1988-09-13 Janssen Pharmaceutica N.V. Herbicidal imidazole-5-carboxylic acid derivatives
PL149675B1 (pl) * 1986-03-10 1990-03-31 Sposób wytwarzania nowych pochodnych kwasu 1-metyl0-1h-imidaz0l0karb0ksyl0weg0-5
US4851424A (en) 1986-06-06 1989-07-25 Ciba-Geigy Corporation 1-Phenyl-lower alkyl-imidazole 4- or 5-carboxamide compounds which are useful in the treatment of epilepsy
DD260928A5 (de) * 1986-06-06 1988-10-12 Ciba-Geigy Ag,Ch Verfahren zur herstellung neuer aralkylimidizolderivate
JPH08119936A (ja) 1994-10-18 1996-05-14 Fujisawa Pharmaceut Co Ltd 複素環式誘導体
IT1295405B1 (it) * 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
CA2416946A1 (en) * 2000-07-28 2003-01-22 Sumitomo Pharmaceuticals Co., Ltd. Pyrrole derivatives
JP3999128B2 (ja) 2001-02-22 2007-10-31 帝人株式会社 ベンゾ[b]チオフェン誘導体、およびその製造方法
AU2003902828A0 (en) * 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
CN103819419B (zh) * 2008-09-04 2016-12-07 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
JP2010202575A (ja) * 2009-03-03 2010-09-16 Takeda Chem Ind Ltd 複素環化合物
CN102035579B (zh) * 2009-09-28 2014-09-03 夏普株式会社 信息反馈方法和用户设备
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
JP5485811B2 (ja) * 2010-06-23 2014-05-07 株式会社ジャパンディスプレイ 双方向シフトレジスタ、及びこれを用いた画像表示装置
UY33554A (es) 2010-08-11 2012-02-29 Millennium Pharm Inc Heteroarilos y usos de los mismos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918377A (zh) * 2007-11-27 2010-12-15 亚德生化公司 新颖化合物和组合物以及使用方法
WO2009148599A1 (en) * 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
CN102548964A (zh) * 2009-07-10 2012-07-04 通用医疗公司 不抑制肾上腺皮质类固醇合成的依托咪酯类似物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANZ EFFENBERGER ET AL.,: "Zur Reaktion von Pyroglutaminsaure-Derivaten mit Phosphorpentachlorid -Darstellung chlorierter Pyrrol-2-carbonsaure-Derivate", 《CHEM. BER.》 *

Also Published As

Publication number Publication date
AR093468A1 (es) 2015-06-10
EP2944633A4 (en) 2016-01-06
AU2017204665A1 (en) 2017-07-27
PT2944633T (pt) 2018-05-09
CN104797570B (zh) 2017-11-07
BR112015010977A2 (pt) 2017-07-11
LT2944633T (lt) 2018-03-12
NO2944633T3 (enExample) 2018-06-30
PH12015501037A1 (en) 2015-07-27
JP6293068B2 (ja) 2018-03-14
SG11201503770VA (en) 2015-06-29
SG10201705852PA (en) 2017-08-30
RS57090B1 (sr) 2018-06-29
SA515360431B1 (ar) 2017-11-15
US9637469B2 (en) 2017-05-02
IL243193A0 (en) 2016-02-29
CL2015001279A1 (es) 2015-06-26
HUE037736T2 (hu) 2018-09-28
IL238539A (en) 2017-11-30
MA38078A1 (fr) 2016-09-30
MA38078B1 (fr) 2017-04-28
SMT201800322T1 (it) 2018-07-17
UA117359C2 (uk) 2018-07-25
IL238539A0 (en) 2015-06-30
AU2013345894A9 (en) 2015-11-12
JPWO2014077285A1 (ja) 2017-01-05
AU2013345894B2 (en) 2017-05-25
EP2944633A1 (en) 2015-11-18
JP2015091865A (ja) 2015-05-14
HK1211940A1 (en) 2016-06-03
CY1120127T1 (el) 2018-12-12
TWI666205B (zh) 2019-07-21
MX2015003672A (es) 2015-06-15
ES2662444T3 (es) 2018-04-06
PE20150974A1 (es) 2015-07-04
EP2944633B1 (en) 2018-01-31
RU2015122698A (ru) 2017-01-10
PL2944633T3 (pl) 2018-08-31
SI2944633T1 (en) 2018-06-29
KR20150082194A (ko) 2015-07-15
HRP20180451T1 (hr) 2018-06-01
US20170190694A1 (en) 2017-07-06
ZA201503322B (en) 2016-01-27
US20150284358A1 (en) 2015-10-08
JP5774238B2 (ja) 2015-09-09
ME03016B (me) 2018-10-20
EP3339302A1 (en) 2018-06-27
CN104797570A (zh) 2015-07-22
WO2014077285A1 (ja) 2014-05-22
TW201422603A (zh) 2014-06-16
CA2891408A1 (en) 2014-05-22
DK2944633T3 (en) 2018-03-12
NZ708031A (en) 2018-04-27
RU2640588C2 (ru) 2018-01-10
AU2013345894A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
CN107721931A (zh) 吡啶衍生物
JP5933746B2 (ja) イミダゾリジンジオン系化合物およびその用途
KR102474640B1 (ko) 카르복실산 화합물, 이의 제조방법, 및 이의 용도
CN104940200A (zh) 多取代芳族化合物作为凝血酶的抑制剂
CN115785068A (zh) Kif18a抑制剂
CN111148735B (zh) 含氮杂芳基化合物及其药物用途
AU2015281021A1 (en) Salt of halogen-substituted heterocyclic compound
JP2013212994A (ja) 新規チオフェンカルボキサミド誘導体及びその医薬用途
EP2980085B1 (en) Pyrazole derivative
CN106458998A (zh) 吡嗪衍生物
HK1246280A1 (en) Pyridine derivative
CN105085359A (zh) 含氮杂环取代的吡咯烷甲酰基硫代吗啉类dpp-iv抑制剂
KR20120095838A (ko) 신규 티오펜 카르복스아미드 유도체 및 그의 의약 용도
EP1854787A1 (en) Novel cyclic compound having quinolylalkylthio group
CN105566263A (zh) 一类新型含氮杂环衍生物、其制备方法及其作为药物的用途
WO2022037601A1 (zh) 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
CN102432592A (zh) 具有抗肿瘤作用的芳基脲衍生物及其制备方法
HK40027595A (en) Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof
HK1211940B (zh) 吡啶衍生物
HK1230192A1 (en) Pyrazine derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1246280

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180223

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1246280

Country of ref document: HK